Compass Pathways plc partners with Osmind to evaluate how psychedelic therapies like COMP360 could be delivered nationwide in community psychiatry settings.
Written By: Pharmacally Medical News Desk
Compass Pathways plc has announced a new collaboration with Osmind aimed at understanding how small- to medium-sized psychiatry clinics nationwide could deliver psychedelic therapies, if such treatments receive regulatory approval.
The partnership focuses on informing real-world care models for COMP360, Compass Pathways’ investigational psilocybin-based therapy for mental health conditions. The companies will assess operational, clinical, and infrastructure requirements needed to integrate these treatments into community-based psychiatric practices.
Osmind operates a nationwide network of more than 1,000 interventional psychiatry clinics, making it one of the largest such networks in the United States. The company provides specialized software and services designed to help independent practices adopt and sustain innovative psychiatric treatments while maintaining operational independence.
Through this collaboration, Compass Pathways aims to expand its understanding of how COMP360 could be delivered across diverse care settings. The initiative builds on the company’s broader strategy to establish partnerships that evaluate scalable and standardized approaches to treatment delivery.
Dr. Steve Levine, Chief Patient Officer at Compass Pathways, emphasized that a key objective is ensuring that COMP360 can be administered safely and effectively in routine clinical environments. He noted that working with Osmind’s network will help the company better understand the practical needs of independent clinics and support the development of patient-centered care models.
Jimmy Qian, Co-Founder and President of Osmind, highlighted that independent psychiatry practices often face barriers in adopting new treatments due to operational complexity. He stated that the collaboration combines Osmind’s expertise in practice management with Compass Pathways’ scientific capabilities to explore how emerging psychedelic therapies can be integrated into everyday clinical practice while maintaining safety, quality, and accessibility.
The collaboration will generate insights into how innovative mental health treatments could be implemented more broadly, particularly in community settings where most patients receive care.
COMP360, Compass Pathways’ proprietary synthetic psilocybin formulation, is currently in late-stage clinical development for treatment-resistant depression and has received Breakthrough Therapy designation from the U.S. Food and Drug Administration, reflecting its potential to address unmet medical need. The company is progressing toward regulatory submission, supported by data from its Phase 3 clinical program.
Separately, recent U.S. policy developments have signalled increased federal attention on psychedelic therapies. An executive order issued by Donald Trump aims to accelerate research and regulatory pathways for such treatments. Compass Pathways has acknowledged the initiative, indicating alignment with efforts to expand patient access while maintaining regulatory and clinical standards.
This collaboration represents a practical step toward enabling the responsible and scalable integration of psychedelic therapies into routine clinical practice, with the goal of improving accessibility for patients in real-world care settings.
Reference